Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT04700436
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 146 participants
- Registry
-
NCT04700436
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04700436. Randomized; no masking; primary purpose treatment. Start 2020-01-03 (actual); primary completion 2021-05-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
- Acronym
- REMBRANDT
- Condition
- Endocrine System Diseases
- Condition
- Nutritional and Metabolic Diseases
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Dyslipidemias
- Intervention (Drug)
- Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
- Intervention (Drug)
- Suvast tablet 10 mg (Rosuvastatin 10 mg)
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Gangnam Severance Hospital
Record details
- Record id
cardio:ct-nct04700436- Content hash
7d941adcf770f11a19e7d9f150dd2497a46cd0af495b42efa2b6f0f6c94f80d3